Bayer Logo Bayer Logo Bayer Logo Bayer Logo

Discover the power of Jivi

EHL rFVIIIs are not the same: The difference is Jivi

JIVI Logo
1

Fewer Infusions:

Jivi delivers powerful protection with a 1x weekly dosing option1*

Read more

Joint Bleed Protection:

Jivi has over 5 years of proven joint bleed protection2,3

Read more

Superior PK and the
benefits of elevated levels:

Jivi delivers higher and more sustained FVIII levels vs other EHL FVIIIs and non-factor replacement therapy4,7

Read more

Proven Safety:

Jivi has the reassurance of >5 years of proven safety5,6

Read more

Fewer Infusions:

Jivi delivers powerful protection with a 1x weekly dosing option1*

Read more

Joint Bleed Protection:

Jivi has up to 7 years of proven joint bleed protection2

Read more

Superior PK and the
benefits of elevated levels:

Jivi delivers higher and more sustained FVIII levels vs other EHL FVIIIs and non-factor replacement therapy4,7,8

Read more

Proven Safety:

Jivi has the reassurance of up to 7 years of proven safety2,5,6

Read more

See how Jivi can help your patients get more out of life

<[style-guide:content_type_videos:ct-videos-player-title-heading-element] class="coh-heading description-video-title ssa-instance-1374094499 coh-ce-cpt_video_player-b2b6571e"> Video title
YYMMDD Author/Uploaded by

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.


* Please refer to local prescribing information. Not all patients are candidates for 1x weekly dosing. In non-EU countries other FVIII treatments may have previously launched – or are currently available – which also offer 1x weekly dosing.
† Based on head-to-head studies comparing the pharmacokinetic profiles of Jivi vs. rFVIII-Fc and Jivi vs. rurioctocog alfa pegol
‡ At extension completion, patients received Jivi for a median (range) total time of 3.9 (0.8–7.0) years with 223 (23–698) exposure days

References